Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common stock 2023 Neurocrine Collaborative Agreement	Common stock 2023 Novartis Collaboration Agreement	Common stock	Additional paid-in capital 2023 Neurocrine Collaborative Agreement	Additional paid-in capital 2023 Novartis Collaboration Agreement	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit	2023 Neurocrine Collaborative Agreement	2023 Novartis Collaboration Agreement	Total
Stockholders' Equity, Beginning Balance at Dec. 31, 2022			$ 38			$ 452,713	$ (219)	$ (393,512)			$ 59,020
Shares, Outstanding, Beginning Balance at Dec. 31, 2022			38,613,891
Exercises of vested stock options						185					185
Exercises of vested stock options (in shares)			51,993
Vesting of restricted stock units (in shares)			374,417
Issuance of common stock	$ 5			$ 31,116					$ 31,121
Issuance of common stock (in shares)	4,395,588
Stock based compensation expense						2,504					2,504
Unrealized gain (loss) on available-for-sale securities, net of tax							87				87
Net income (loss)								124,044			124,044
Stockholders' Equity, Ending Balance at Mar. 31, 2023			$ 43			486,518	(132)	(269,468)			216,961
Shares, Outstanding, Ending Balance at Mar. 31, 2023			43,435,889
Stockholders' Equity, Beginning Balance at Dec. 31, 2022			$ 38			452,713	(219)	(393,512)			59,020
Shares, Outstanding, Beginning Balance at Dec. 31, 2022			38,613,891
Unrealized gain (loss) on available-for-sale securities, net of tax											(29)
Net income (loss)											75,935
Stockholders' Equity, Ending Balance at Sep. 30, 2023			$ 44			494,001	(248)	(317,577)			176,220
Shares, Outstanding, Ending Balance at Sep. 30, 2023			43,909,161
Stockholders' Equity, Beginning Balance at Mar. 31, 2023			$ 43			486,518	(132)	(269,468)			216,961
Shares, Outstanding, Beginning Balance at Mar. 31, 2023			43,435,889
Exercises of vested stock options			$ 1			1,228					1,229
Exercises of vested stock options (in shares)			198,348
Vesting of restricted stock units (in shares)			62,828
Issuance of common stock under ESPP						418					418
Issuance of common stock under ESPP (in shares)			62,344
Stock based compensation expense						2,627					2,627
Unrealized gain (loss) on available-for-sale securities, net of tax							(1)				(1)
Net income (loss)								(22,208)			(22,208)
Stockholders' Equity, Ending Balance at Jun. 30, 2023			$ 44			490,791	(133)	(291,676)			199,026
Shares, Outstanding, Ending Balance at Jun. 30, 2023			43,759,409
Exercises of vested stock options						415					415
Exercises of vested stock options (in shares)			127,252
Vesting of restricted stock units (in shares)			22,500
Stock based compensation expense						2,795					2,795
Unrealized gain (loss) on available-for-sale securities, net of tax							(115)				(115)
Net income (loss)								(25,901)			(25,901)
Stockholders' Equity, Ending Balance at Sep. 30, 2023			$ 44			494,001	(248)	(317,577)			176,220
Shares, Outstanding, Ending Balance at Sep. 30, 2023			43,909,161
Stockholders' Equity, Beginning Balance at Dec. 31, 2023			$ 44			497,506	(48)	(261,182)			236,320
Shares, Outstanding, Beginning Balance at Dec. 31, 2023			44,038,333
Exercises of vested stock options						78					78
Exercises of vested stock options (in shares)			32,500
Vesting of restricted stock units (in shares)			324,520
Issuance of common stock		$ 2			$ 19,303					$ 19,305
Issuance of common stock (in shares)		2,145,002
Issuance of common stock and pre-funded warrants in connection with underwritten public offering			$ 8			93,465					93,473
Issuance of common stock and pre-funded warrants in connection with underwritten public offering (in shares )			7,777,778
Stock based compensation expense						3,498					3,498
Unrealized gain (loss) on available-for-sale securities, net of tax							(458)				(458)
Net income (loss)								(11,330)			(11,330)
Stockholders' Equity, Ending Balance at Mar. 31, 2024			$ 54			613,850	(506)	(272,512)			340,886
Shares, Outstanding, Ending Balance at Mar. 31, 2024			54,318,133
Stockholders' Equity, Beginning Balance at Dec. 31, 2023			$ 44			497,506	(48)	(261,182)			$ 236,320
Shares, Outstanding, Beginning Balance at Dec. 31, 2023			44,038,333
Exercises of vested stock options (in shares)											86,100
Unrealized gain (loss) on available-for-sale securities, net of tax											$ 15
Net income (loss)											(30,515)
Stockholders' Equity, Ending Balance at Sep. 30, 2024			$ 55			621,985	(33)	(291,697)			330,310
Shares, Outstanding, Ending Balance at Sep. 30, 2024			54,542,048
Stockholders' Equity, Beginning Balance at Mar. 31, 2024			$ 54			613,850	(506)	(272,512)			340,886
Shares, Outstanding, Beginning Balance at Mar. 31, 2024			54,318,133
Exercises of vested stock options						90					90
Exercises of vested stock options (in shares)			25,958
Vesting of restricted stock units (in shares)			56,549
Issuance of common stock under ESPP						639					639
Issuance of common stock under ESPP (in shares)			71,473
Stock based compensation expense						3,959					3,959
Unrealized gain (loss) on available-for-sale securities, net of tax							(16)				(16)
Net income (loss)								(10,141)			(10,141)
Stockholders' Equity, Ending Balance at Jun. 30, 2024			$ 54			618,538	(522)	(282,653)			335,417
Shares, Outstanding, Ending Balance at Jun. 30, 2024			54,472,113
Exercises of vested stock options						92					92
Exercises of vested stock options (in shares)			27,642
Vesting of restricted stock units			$ 1								1
Vesting of restricted stock units (in shares)			42,293
Stock based compensation expense						3,355					3,355
Unrealized gain (loss) on available-for-sale securities, net of tax							489				489
Net income (loss)								(9,044)			(9,044)
Stockholders' Equity, Ending Balance at Sep. 30, 2024			$ 55			$ 621,985	$ (33)	$ (291,697)			$ 330,310
Shares, Outstanding, Ending Balance at Sep. 30, 2024			54,542,048